JP2024502473A5 - - Google Patents

Info

Publication number
JP2024502473A5
JP2024502473A5 JP2023541528A JP2023541528A JP2024502473A5 JP 2024502473 A5 JP2024502473 A5 JP 2024502473A5 JP 2023541528 A JP2023541528 A JP 2023541528A JP 2023541528 A JP2023541528 A JP 2023541528A JP 2024502473 A5 JP2024502473 A5 JP 2024502473A5
Authority
JP
Japan
Prior art keywords
group
independently selected
substituted
ring atoms
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502473A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011551 external-priority patent/WO2022150549A1/en
Publication of JP2024502473A publication Critical patent/JP2024502473A/ja
Publication of JP2024502473A5 publication Critical patent/JP2024502473A5/ja
Pending legal-status Critical Current

Links

JP2023541528A 2021-01-08 2022-01-07 Sting活性に関連する状態を治療するためのオキサルアミド化合物および組成物 Pending JP2024502473A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135303P 2021-01-08 2021-01-08
US63/135,303 2021-01-08
PCT/US2022/011551 WO2022150549A1 (en) 2021-01-08 2022-01-07 Oxalamide compounds and compositions for treating conditions associated with sting activity

Publications (2)

Publication Number Publication Date
JP2024502473A JP2024502473A (ja) 2024-01-19
JP2024502473A5 true JP2024502473A5 (cg-RX-API-DMAC7.html) 2025-01-15

Family

ID=80123502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541528A Pending JP2024502473A (ja) 2021-01-08 2022-01-07 Sting活性に関連する状態を治療するためのオキサルアミド化合物および組成物

Country Status (5)

Country Link
US (1) US20240083879A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274826A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502473A (cg-RX-API-DMAC7.html)
CN (1) CN116964045A (cg-RX-API-DMAC7.html)
WO (1) WO2022150549A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
US20260137687A1 (en) * 2022-08-24 2026-05-21 The Regents Of The University Of California GTPase INHIBITORS AND USES THEREOF
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
ATE375349T1 (de) * 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
CN102264736B (zh) * 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
WO2012075380A1 (en) 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors
CA2944198C (en) * 2013-04-26 2021-11-16 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
AU2014340269B2 (en) 2013-10-21 2018-06-21 Drexel University Use of STING agonists to treat chronic hepatitis B virus infection
TWI873098B (zh) * 2018-07-03 2025-02-21 瑞士商諾華製藥公司 用於治療與sting活性相關之病症的化合物及組合物
WO2020236586A1 (en) * 2019-05-17 2020-11-26 Ifm Due, Inc. N-hetaryl-squaramide compounds for treating conditions associated with sting activity
WO2021067791A1 (en) * 2019-10-03 2021-04-08 Ifm Due, Inc. Oxalamide compounds and compositions for treating conditions associated with sting activity

Similar Documents

Publication Publication Date Title
JP2023509422A5 (cg-RX-API-DMAC7.html)
JP2022536755A5 (cg-RX-API-DMAC7.html)
JP2022550640A5 (cg-RX-API-DMAC7.html)
JP2022535743A5 (cg-RX-API-DMAC7.html)
JP2022544714A5 (cg-RX-API-DMAC7.html)
HRP20171294T1 (hr) Derivati fenilamid 4-(benzil)-piperazin-1-karboksilne kiseline i slični spojevi kao modulatori amidazne hidrolaze masne kiseline (faah) za liječenje tjeskobe, boli i drugih stanja
JP2022538301A5 (cg-RX-API-DMAC7.html)
JP2021105002A5 (cg-RX-API-DMAC7.html)
JP2012507522A5 (cg-RX-API-DMAC7.html)
JP2004509855A (ja) TNFαインヒビターとして有用なクマリン誘導体
JP2020517677A5 (cg-RX-API-DMAC7.html)
WO2017160861A1 (en) Inhibitors for soluble epoxide hydrolase (seh) and fatty acid amide hydrolase (faah)
RU2013150349A (ru) 5-замещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов васе, содержащие их композиции и их применение
RU2019129299A (ru) Модуляторы глюкокортикоидного рецептора для лечения рака шейки матки
CA2457444A1 (en) 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
JP2021530560A5 (cg-RX-API-DMAC7.html)
JP2024529527A5 (cg-RX-API-DMAC7.html)
JP2019513745A5 (cg-RX-API-DMAC7.html)
AU2021273001A1 (en) ENPP1 modulators and uses thereof
JP2020521766A5 (cg-RX-API-DMAC7.html)
ES2525298T3 (es) Compuestos heterocíclicos como agonistas del S1P1 para el tratamiento de enfermedades autoinmunes y vasculares
JP2019510794A5 (cg-RX-API-DMAC7.html)
JP2010520884A5 (cg-RX-API-DMAC7.html)
RU2010113358A (ru) Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов
JP2025530222A (ja) 2-置換ピペリジン誘導体、その製造方法及び医薬的用途